Stock info Theravance Biopharma Inc. | Filter  Basic-Info

Theravance Biopharma Inc.

The core activities of Theravance Biopharma Inc. are in the pharmaceutical sector. The global pharmaceutical companies gained around 75 percent worldwide over the last 10 years. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.

The past year was a good year for Theravance Biopharma Inc. investors

Over the period from December 2015 till December 2016 the stock gained around 106 percent. Over the period 2011-2016 the stock lost a modest 0 percent. Theravance Biopharma Inc.'s revenues between 2011 and 2015 were far from constant and moved between 130,15 million dollars and 42,13 million dollars. Theravance Biopharma Inc.'s net results between 2011 and 2015 were far from constant and moved between -109,34 million dollars and -182,22 million dollars.

Over the past 5 years the American company paid out dividends.

Quite a lot of debt Theravance Biopharma Inc.

At the end of 2015 the American company had a balance sheet of 300,12 million dollars. At the end of 2015 the total debt positon equaled 57,05 million dollars. This is around 19,01 percent of the total balance sheet. The American company's price/earnings-ratio was -3. So the market valued the stock at -3 times the 2015' earnings per share. We could say that based on her price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the pharmaceutical company equaled around 616,81 million dollars. At the end of 2015 the American company had around 37,98 million stocks listed on the exchanges.

At this page you find all Theravance Biopharma Inc.'s financial reports. More information about Theravance Biopharma Inc. can be found it's website. .